During the past decade, Nebraska Cancer Research Center conducted 182 clinical trials. In the 10-year time frame, 182 clinical trials started and 113 clinical trials were completed, i.e. on average, 62.1% percent of trials that started reached the finish line to date. In the past 5 years, 84 clinical trials started and 69 clinical trials were completed. i.e. 82.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nebraska Cancer Research Center" #1 sponsor was "National Cancer Institute (NCI)" with 72 trials, followed by "SWOG Cancer Research Network" with 19 trials sponsored, "Alliance for Clinical Trials in Oncology" with 16 trials sponsored, "Bristol-Myers Squibb" with 11 trials sponsored and "Novartis Pharmaceuticals" with 11 trials sponsored. Other sponsors include 143 different institutions and companies that sponsored additional 93 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nebraska Cancer Research Center" #1 collaborator was "National Cancer Institute (NCI)" with 50 trials as a collaborator, "Merck Sharp & Dohme LLC" with 13 trials as a collaborator, "NRG Oncology" with 9 trials as a collaborator, "Bristol-Myers Squibb" with 6 trials as a collaborator and "Hoosier Cancer Research Network" with 6 trials as a collaborator. Other collaborators include 70 different institutions and companies that were collaborators in the rest 57 trials.

According to Clinical.Site data, the most researched conditions in "Nebraska Cancer Research Center" are "Breast Cancer" (20 trials), "Melanoma" (14 trials), "Colorectal Cancer" (9 trials), "Recurrent Squamous Cell Lung Carcinoma" (9 trials) and "Renal Cell Carcinoma" (9 trials). Many other conditions were trialed in "Nebraska Cancer Research Center" in a lesser frequency.

Most popular intervention types in "Nebraska Cancer Research Center" are "Drug" (236 trials), "Other" (100 trials), "Biological" (75 trials), "Procedure" (24 trials) and "Radiation" (15 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (58 trials), "Quality-of-Life Assessment" (34 trials), "Pembrolizumab" (26 trials), "Placebo" (24 trials) and "Nivolumab" (22 trials). Other intervention names were less common.

The vast majority of trials in "Nebraska Cancer Research Center" are 224 trials for "All" genders, 27 trials for "Female" genders and 22 trials for "Male" genders.

Currently, there are NaN active trials in "Nebraska Cancer Research Center". undefined are not yet recruiting, 75 are recruiting, 93 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 70 completed trials in Nebraska Cancer Research Center, 2 suspended trials, and 26 terminated clinical trials to date.

Out of the total trials that were conducted in Nebraska Cancer Research Center, 47 "Phase 1" clinical trials were conducted, 122 "Phase 2" clinical trials and 117 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 3 trials that are defined as “Not Applicable".

Nebraska Cancer Research Center has several departments that took part in Clinical trials: "Nebraska Cancer Specialists,8303 Dodge Street" - 2 trials, "Nebraska Cancer Specialist/Missouri Valley Cancer Consortium" - 2 trials